99 related articles for article (PubMed ID: 8270491)
1. Effect of conagenin in tumor bearing mice. Antitumor activity, generation of effector cells and cytokine production.
Kawatsu M; Yamashita T; Osono M; Masuda T; Ishizuka M; Takeuchi T
J Antibiot (Tokyo); 1993 Nov; 46(11):1692-8. PubMed ID: 8270491
[TBL] [Abstract][Full Text] [Related]
2. Antitumor cells found in tumor-bearing mice given ubenimex.
Ishizuka M; Masuda T; Mizutani S; Takeuchi T; Umezawa H
J Antibiot (Tokyo); 1987 May; 40(5):697-701. PubMed ID: 3497141
[TBL] [Abstract][Full Text] [Related]
3. T cell activation by conagenin in mice.
Kawatsu M; Yamashita T; Osono M; Ishizuka M; Takeuchi T
J Antibiot (Tokyo); 1993 Nov; 46(11):1687-91. PubMed ID: 8270490
[TBL] [Abstract][Full Text] [Related]
4. Improvement of efficacy of antitumor agents by conagenin.
Kawatsu M; Yamashita T; Ishizuka M; Takeuchi T
J Antibiot (Tokyo); 1995 Mar; 48(3):222-5. PubMed ID: 7730156
[TBL] [Abstract][Full Text] [Related]
5. Augmentation of murine natural killer cell and antibody dependent cellular cytotoxicity activities by Phyllanthus emblica, a new immunomodulator.
Suresh K; Vasudevan DM
J Ethnopharmacol; 1994 Aug; 44(1):55-60. PubMed ID: 7990505
[TBL] [Abstract][Full Text] [Related]
6. Effect of conagenin on thrombocytopenia induced by antitumor agents in mice.
Kawatsu M; Yamashita T; Ishizuka M; Takeuchi T
J Antibiot (Tokyo); 1994 Oct; 47(10):1123-9. PubMed ID: 7961162
[TBL] [Abstract][Full Text] [Related]
7. Modulation by conagenin of inflammatory mediator productions in mice given 5-fluorouracil.
Kawatsu M; Yamashita T; Ishizuka M; Takeuchi T
Anticancer Res; 1997; 17(2A):917-22. PubMed ID: 9137428
[TBL] [Abstract][Full Text] [Related]
8. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
Fuyama S; Yamamoto H; Fujii Y; Arai S
Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
[TBL] [Abstract][Full Text] [Related]
10. Modification of host antitumor defense mechanisms in mice by progressively growing tumor.
Maccubbin DL; Mace KF; Ehrke MJ; Mihich E
Cancer Res; 1989 Aug; 49(15):4216-24. PubMed ID: 2525950
[TBL] [Abstract][Full Text] [Related]
11. Improvement of intestinal toxicity of 5-fluorouracil by conagenin, a low molecular immunomodulator.
Kawatsu M; Yamashita T; Ishizuka M; Takeuchi T
Anticancer Res; 1996; 16(5A):2937-41. PubMed ID: 8917410
[TBL] [Abstract][Full Text] [Related]
12. Effect of bestatin on syngeneic tumors in mice.
Abe F; Shibuya K; Uchida M; Takahashi K; Horinishi H; Matsuda A; Ishizuka M; Takeuchi T; Umezawa H
Gan; 1984 Jan; 75(1):89-94. PubMed ID: 6586596
[TBL] [Abstract][Full Text] [Related]
13. Lipoteichoic acid of Bifidobacterium in combination with 5-fluorouracil inhibit tumor growth and relieve the immunosuppression.
Xie N; Wang Y; Wang Q; Li FR; Guo B
Bull Cancer; 2012 May; 99(5):E55-63. PubMed ID: 22522606
[TBL] [Abstract][Full Text] [Related]
14. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.
Yang YF; Zou JP; Mu J; Wijesuriya R; Ono S; Walunas T; Bluestone J; Fujiwara H; Hamaoka T
Cancer Res; 1997 Sep; 57(18):4036-41. PubMed ID: 9307290
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma.
Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Kurimoto M
Cancer Res; 1997 Oct; 57(20):4557-63. PubMed ID: 9377569
[TBL] [Abstract][Full Text] [Related]
16. The role of anti-asialo GM1 antibody-sensitive cells in the implementation of tumor-specific T cell-mediated immunity in vivo.
Yoshioka T; Sato S; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1986 Aug; 77(8):825-32. PubMed ID: 3093429
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of cytogenin.
Kumagai H; Masuda T; Ishizuka M; Takeuchi T
J Antibiot (Tokyo); 1995 Feb; 48(2):175-8. PubMed ID: 7706130
[TBL] [Abstract][Full Text] [Related]
18. The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers.
Ichikawa T; Lamb JC; Christensson PI; Hartley-Asp B; Isaacs JT
Cancer Res; 1992 Jun; 52(11):3022-8. PubMed ID: 1591718
[TBL] [Abstract][Full Text] [Related]
19. The influence of tumor immunity suppressors on the effector stage of human and animal lymphokine-activated killer cells.
Abronina IF; Indrova M; Bubenic J; Figurin KM; Malakhova NV; Bykovskaya SN
Biomed Pharmacother; 1993; 47(9):371-7. PubMed ID: 8068858
[TBL] [Abstract][Full Text] [Related]
20. Augmentation of the antimetastatic effect of anticoagulant drugs by immunostimulation in mice.
Gorelik E
Cancer Res; 1987 Feb; 47(3):809-15. PubMed ID: 3802083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
